胶质瘤的补充与替代医学:当前文献的系统综述与批判性评价
该研究系统检索胶质瘤补充与替代医学(CAM)的体外、动物及临床研究,共分析378项研究(315篇独特文章),其中体外274项(73%)、动物77项(20%)、临床26项(7%,2491例患者)。白藜芦醇是体外(62项)和体内(17项)研究中最常探讨的CAM疗法。26项临床研究中7项未发现临床效果,5项报告可能影响无进展生存或总生存,3项显示肿瘤进展减缓或停止,2项显示对症状和生活质量有积极影响。
要点
- 共分析378项研究(315篇独特文章),以体外研究为主(274项,73%),临床研究仅26项(7%,2491例患者)。
- 白藜芦醇是体外(62项)和体内(17项)研究中最常探讨的CAM疗法。
- 26项临床研究中7项未发现临床效果,5项报告可能影响无进展生存或总生存。
核心结论
- 这些发现有望教育医疗提供者和患者,并促进胶质瘤CAM治疗领域的进一步研究。
研究设计与样本
- 对胶质瘤CAM疗法的体外、动物和临床研究(英文,所有可获取年份)进行详尽的电子文献检索。
- 共分析378项研究(315篇独特文章),包括体外274项(73%)、动物77项(20%)、临床26项(7%,2491例患者)。
- 研究最多来自中国(n=135,43%),其次为美国(n=62,20%)和西班牙(n=17,5%-6%)。
主要发现
- 体外研究(60%)和动物研究(56%)中最常见的终点是细胞毒性,其次是化疗协同作用及抑制侵袭和迁移。
- 安全性/毒性检查:体外研究21%(相同剂量下48%有细胞毒性),动物研究39%(无器官毒性证据),临床研究50%(6项报告不良事件)。
- 26项临床研究中7项未发现临床效果,5项报告可能影响无进展生存或总生存,3项显示肿瘤进展减缓或停止,2项显示对症状和生活质量有积极影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with glioma and their caregivers seek complementary and alternative medicine (CAM) methods to comfort themselves, cope with cancer medication side effects, and feel they are taking control of their disease. OBJECTIVE: To summarize existing evidence on safety and efficacy of CAM treatments for gliomas. METHODS: We performed an exhaustive electronic literature search for in vitro, animal, and clinical studies (English language, all years available) on CAM modalities for gliomas. RESULTS: A total of 378 studies (315 unique articles) were analyzed. Distribution was as follows: in vitro-274 (73%), animal-77 (20%), and clinical-26 (7%, 2491 patients). Most studies were conducted in China (n = 135, 43%), followed by the United States (n = 62, 20%) and Spain (n = 17, 5%-6%). Resveratrol was the most commonly investigated CAM therapy in the in vitro (n = 62) and in vivo (n = 17) setting. Safety/toxicity was examined in 21% of in vitro (cytotoxic at same dose in 48%), 39% of in vivo (no evidence of organ toxicity), and 50% of clinical studies (adverse events reported in 6). Cytotoxicity was the most frequent end point among in vitro (60%) and animal studies (56%), followed by synergistic action with chemotherapy and inhibition of invasiveness and migration. Finally, 7 of 26 studies found no clinical effect, whereas 5 reported possible impact on progression-free or overall survival, 3 demonstrated decrease or arrest of tumor progression, and 2 showed positive impact on symptoms and quality of life. CONCLUSION: These findings will hopefully educate providers and patients and stimulate further research in the field of CAM therapy for gliomas.
引用
- Kerezoudis P, Kerezoudi EN, Choudhry A, et al. Complementary and Alternative Medicine for Gliomas: Systematic Review and Critical Appraisal of Current Literature. Neurosurgery. 2022. PMID: 36650046. doi:10.1227/neu.0000000000002236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。